- Prostate Cancer
- Medical Oncology
- Renal Cell Carcinoma (RCC)
- Urologic Oncology
- Upper Tract Urothelial Carcinoma (UTUC)
- PARP Inhibitors
- Immunotherapy
- Clinical Trials
- Kidney Cancer
- Bladder Cancer
Do you need a recap of the latest urologic oncology research presented at GU ASCO 2025? This episode of BackTable Urology features a multidisciplinary discussion among three leading voices in urology and medical oncology – Drs. Bogdana Schmidt, Shilpa Gupta, and Ben Maughan – covering the most notable results presented at this year’s meeting.
This podcast is supported by
Timestamps
Resources
More about this episode
First, the doctors cover a wide range of topics including PARP inhibitors for prostate cancer, HER2-targeting antibody drug conjugates in bladder cancer, adjuvant chemotherapy for upper tract urothelial carcinoma, and biomarkers such as KIM-1 in kidney cancer. Highlighting the importance of multidisciplinary collaboration, the experts also critique the COSMIC-313 trial and discuss the nuances of applying new therapeutic combinations in real-world clinical practice.


